(PharmaNewsWire.Com, June 07, 2017 ) Nasopharyngeal cancer is a rare type of head and neck cancer. It starts in the upper part of your throat, behind the nose. This area is called the nasopharynx. The risk factors of nasopharyngeal cancer may include Epstein-Barr virus. Symptoms of nasopharyngeal cancer may include blurry or double vision, difficulty speaking, including hoarseness, ear infections that keep coming back, face pain or numbness, headache, hearing loss, ringing in the ears. Treatment includes surgery, chemotherapy and radiation therapy.
Report Highlights Pharmaceutical and Healthcare latest pipeline guide Nasopharyngeal Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Nasopharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Nasopharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 9, 12, 9 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 7, 2 and 6 molecules, respectively.
Nasopharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Nasopharyngeal Cancer (Oncology) . - The pipeline guide reviews pipeline therapeutics for Nasopharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Nasopharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Nasopharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Nasopharyngeal Cancer (Oncology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Nasopharyngeal Cancer (Oncology) . - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Nasopharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Advenchen Laboratories LLC Ambrx Inc arGEN-X BV Ascentage Pharma Group Corp Ltd Atara Biotherapeutics Inc AVEO Pharmaceuticals Inc BeiGene Ltd Betta Pharmaceuticals Co Ltd BioDiem Ltd Biomics Biotechnologies Co Ltd CBT Pharmaceuticals Inc Celgene Corp Cell Medica Ltd F. Hoffmann-La Roche Ltd GlaxoSmithKline Plc MedImmune LLC Merck & Co Inc Merck KGaA Millennium Pharmaceuticals Inc Neonc Technologies Inc Novartis AG Ono Pharmaceutical Co Ltd Sapvax Tessa Therapeutics Pte Ltd Theravectys SA Viracta Therapeutics Inc Yabao Pharmaceutical Group Co Ltd
Number of Products under Development for Nasopharyngeal Cancer, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Nasopharyngeal Cancer - Pipeline by Advenchen Laboratories LLC, H1 2017 Nasopharyngeal Cancer - Pipeline by Ambrx Inc, H1 2017 Nasopharyngeal Cancer - Pipeline by arGEN-X BV, H1 2017 Nasopharyngeal Cancer - Pipeline by Ascentage Pharma Group Corp Ltd, H1 2017 Nasopharyngeal Cancer - Pipeline by Atara Biotherapeutics Inc, H1 2017 Nasopharyngeal Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2017 Nasopharyngeal Cancer - Pipeline by BeiGene Ltd, H1 2017 Nasopharyngeal Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H1 2017 Nasopharyngeal Cancer - Pipeline by BioDiem Ltd, H1 2017 Nasopharyngeal Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H1 2017 Nasopharyngeal Cancer - Pipeline by CBT Pharmaceuticals Inc, H1 2017 Nasopharyngeal Cancer - Pipeline by Celgene Corp, H1 2017 Nasopharyngeal Cancer - Pipeline by Cell Medica Ltd, H1 2017 Nasopharyngeal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 Nasopharyngeal Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017 Nasopharyngeal Cancer - Pipeline by MedImmune LLC, H1 2017 Nasopharyngeal Cancer - Pipeline by Merck & Co Inc, H1 2017 Nasopharyngeal Cancer - Pipeline by Merck KGaA, H1 2017 Nasopharyngeal Cancer - Pipeline by Millennium Pharmaceuticals Inc, H1 2017 Nasopharyngeal Cancer - Pipeline by Neonc Technologies Inc, H1 2017 Nasopharyngeal Cancer - Pipeline by Novartis AG, H1 2017 Nasopharyngeal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017 Nasopharyngeal Cancer - Pipeline by Sapvax, H1 2017 Nasopharyngeal Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H1 2017 Nasopharyngeal Cancer - Pipeline by Theravectys SA, H1 2017 Nasopharyngeal Cancer - Pipeline by Viracta Therapeutics Inc, H1 2017 Nasopharyngeal Cancer - Pipeline by Yabao Pharmaceutical Group Co Ltd, H1 2017 Nasopharyngeal Cancer - Dormant Projects, H1 2017 Nasopharyngeal Cancer - Discontinued Products, H1 2017
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
